GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Diamyd Medical AB (OSTO:DMYD B) Future 3-5Y EPS without NRI Growth Rate : -5.44 (As of May. 12, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate is -5.44.

Competitive Comparison of Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Diamyd Medical AB  (OSTO:DMYD B) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Diamyd Medical AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XSAT:HAMLET B OSTO:IBT B OSTO:SYNACT OSTO:SANION OSTO:MAGLE OSTO:FLUO OSTO:ONCO OSTO:CANTA OSTO:INIT OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
DYMDF:USA DMN:Germany
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines